SLI
2.110,61
PKT
-29,71
PKT
-1,39
%
Werbung
Analysen zu SLI-Werten
| Datum | Rating | Analyst | |
|---|---|---|---|
| 05.07.12 | SGS SA buy | Vontobel Research | |
| 05.07.12 | Kühne + Nagel International hold | Vontobel Research | |
| 04.07.12 | Swiss Re neutral | Exane-BNP Paribas SA | |
| 04.07.12 | Holcim sell | Goldman Sachs Group Inc. | |
| 04.07.12 | Holcim neutral | Goldman Sachs Group Inc. | |
| 04.07.12 | Givaudan sell | Deutsche Bank AG | |
| 04.07.12 | Kühne + Nagel International overweight | J.P. Morgan Cazenove | |
| 03.07.12 | Holcim outperform | Exane-BNP Paribas SA | |
| 03.07.12 | Zurich Insurance buy | Nomura | |
| 03.07.12 | Swiss Re buy | Sarasin Research | |
| 03.07.12 | Nestlé kaufen | Norddeutsche Landesbank (Nord/LB) | |
| 03.07.12 | Kühne + Nagel International hold | Vontobel Research | |
| 02.07.12 | Nestlé neutral | Goldman Sachs Group Inc. | |
| 02.07.12 | Geberit kaufen | Euro am Sonntag | |
| 02.07.12 | Julius Bär buy | ING | |
| 02.07.12 | UBS hold | ING | |
| 02.07.12 | UBS sell | ING | |
| 02.07.12 | Swisscom hold | Vontobel Research | |
| 02.07.12 | Schindler kaufen | Die Actien-Börse | |
| 02.07.12 | SGS SA kaufen | Die Actien-Börse | |
| 29.06.12 | Nestlé sector perform | RBC Capital Markets | |
| 28.06.12 | Novartis buy | Deutsche Bank AG | |
| 28.06.12 | UBS neutral | Sarasin Research | |
| 28.06.12 | Novartis outperform | Sanford C. Bernstein and Co., Inc. | |
| 27.06.12 | UBS overweight | J.P. Morgan Cazenove | |
| 27.06.12 | Kühne + Nagel International outperform | Credit Suisse Group | |
| 27.06.12 | Sika buy | Vontobel Research | |
| 26.06.12 | Swiss Life neutral | Goldman Sachs Group Inc. | |
| 26.06.12 | ABB (Asea Brown Boveri) neutral | Exane-BNP Paribas SA | |
| 26.06.12 | UBS outperform | RBC Capital Markets | |
| 26.06.12 | Kühne + Nagel International buy | Nomura | |
| 25.06.12 | UBS buy | Banc of America Securities-Merrill Lynch | |
| 25.06.12 | Holcim neutral | J.P. Morgan Cazenove | |
| 25.06.12 | Zurich Insurance neutral | J.P. Morgan Cazenove | |
| 25.06.12 | Novartis neutral | UBS AG | |
| 25.06.12 | Swiss Re overweight | J.P. Morgan Cazenove | |
| 25.06.12 | UBS neutral | Banc of America Securities-Merrill Lynch | |
| 25.06.12 | Novartis buy | UBS AG | |
| 25.06.12 | UBS kaufen | Die Actien-Börse | |
| 25.06.12 | Sonova buy | Vontobel Research |